Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
Gail P. Risbridger(Discovery Institute), Damien Bolton(Austin Health), David Clouston(TissuPath), J.K. Pedersen(TissuPath), Roxanne Toivanen(The University of Melbourne), Ania Sliwinski(Peter MacCallum Cancer Centre), Mark Frydenberg(Monash University), Renea A. Taylor(The University of Melbourne), Sally M. Hunter(Peter MacCallum Cancer Centre), David Pook, Hong Wang(Zhejiang University of Technology), Jason Li(Queen's University), Declan G. Murphy(Peter Doherty Institute), Heather Thorne(University of Melbourne), Mitchell G. Lawrence(The University of Melbourne), Gillian Mitchell(Peter MacCallum Cancer Centre), Melissa Papargiris(Monash University)
Cited by 137
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k